| [1] |
TUDER R M. Pulmonary vascular remodeling in pulmonary hypertension[J]. Cell Tissue Res, 2017, 367(3): 643-649. doi:10.1007/s00441-016-2539-y .
doi: 10.1007/s00441-016-2539-y
|
| [2] |
罗志梅, 刘虹延, 孙得胜. 一种肺血管基因敲减动物模型的构建及在肺动脉高压中的运用[J]. 实用医学杂志, 2023, 39(4): 404-409. doi:10.3969/j.issn.1006-5725.2023.04.003 .
doi: 10.3969/j.issn.1006-5725.2023.04.003
|
| [3] |
张嘉莹, 樊勇, 张卓莉. 肺动脉高压发病机制中的肺血管重塑[J]. 中华临床免疫和变态反应杂志, 2023, 17(1): 50-55. doi:10.3969/j.issn.1673-8705.2023.01.010 .
doi: 10.3969/j.issn.1673-8705.2023.01.010
|
| [4] |
徐明艳, 韩校鹏, 刘英丽, 等. 慢性阻塞性肺疾病急性加重期并发肺动脉高压的危险因素[J]. 实用医学杂志, 2022, 38(19): 2467-2471.doi:10.3969/j.issn.1006-5725.2022.19.017 .
doi: 10.3969/j.issn.1006-5725.2022.19.017
|
| [5] |
ZAWIA A, ARNOLD N D, WEST L, et al. Altered macrophage polarization induces experimental pulmonary hypertension and is observed in patients with pulmonary arterial hypertension[J]. Arterioscler Thromb Vasc Biol, 2021, 41(1): 430-445. doi:10.1161/ATVBAHA.120.314639 .
doi: 10.1161/ATVBAHA.120.314639
|
| [6] |
LI C, LIU P, SONG R, et al. Immune cells and autoantibodies in pulmonary arterial hypertension[J]. Acta Biochim Biophys Sin, 2017, 49(12): 1047-1057. doi:10.1093/abbs/gmx095 .
doi: 10.1093/abbs/gmx095
|
| [7] |
TARASEVICIENE-STEWART L, KASAHARA Y, ALGER L, et al. Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension[J]. FASEB J, 2001, 15(2): 427-438. doi:10.1096/fj.00-0343com .
doi: 10.1096/fj.00-0343com
|
| [8] |
陈子宜,孙红燕,康品方,等.肺动脉高压动物实验模型的研究进展[J/OL].实验动物与比较医学,1-18[2026-03-02]..
|
| [9] |
COSSARIZZA A, CHANG H D, RADBRUCH A, et al. Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition)[J]. Eur J Immunol, 2019, 49(10): 1457-1973. doi:10.1002/eji.201970107 .
doi: 10.1002/eji.201970107
|
| [10] |
SORKHDINI P, KLUBOCK-SHUKLA K, SHETH S, et al. Type 2 innate immunity promotes the development of pulmonary fibrosis in Hermansky-Pudlak syndrome[J]. JCI Insight, 2024, 9(22): e178381. doi:10.1172/jci.insight.178381 .
doi: 10.1172/jci.insight.178381
|
| [11] |
IKUTANI M, SHIMIZU S, OKADA K, et al. Characterization of long-term interleukin-33 administration as an animal model of pulmonary arterial hypertension[J]. Biochem Biophys Res Commun, 2024, 734: 150750. doi:10.1016/j.bbrc.2024.150750 .
doi: 10.1016/j.bbrc.2024.150750
|
| [12] |
LI N, LI Q, BAI J, et al. The multiple organs insult and compensation mechanism in mice exposed to hypobaric hypoxia[J]. Cell Stress Chaperones, 2020, 25(5): 779-791. doi:10.1007/s12192-020-01117-w .
doi: 10.1007/s12192-020-01117-w
|
| [13] |
SERHAN C N, BRAIN S D, BUCKLEY C D, et al. Resolution of inflammation: State of the art, definitions and terms[J]. FASEB J, 2007, 21(2): 325-332. doi:10.1096/fj.06-7227rev .
doi: 10.1096/fj.06-7227rev
|
| [14] |
KUANG M, CHEN Y, XING Y, et al. Echocardiographic evaluation of right heart failure which might be associated with DNA damage response in SU5416-hypoxia induced pulmonary hypertension rat model[J]. Respir Res, 2023, 24(1): 202. doi:10.1186/s12931-023-02501-7 .
doi: 10.1186/s12931-023-02501-7
|
| [15] |
秦崇, 潘磊, 李佳, 等. 低压低氧肺动脉高压形成中CD4+T细胞亚群的变化[J]. 标记免疫分析与临床, 2024, 31(9): 1580-1588. doi:10.11748/bjmy.issn.1006-1703.2024.09.003 .
doi: 10.11748/bjmy.issn.1006-1703.2024.09.003
|
| [16] |
AYASS M A, TRIPATHI T, ZHU K, et al. T helper (Th) cell profiles and cytokines/chemokines in characterization, treatment, and monitoring of autoimmune diseases[J]. Methods, 2023, 220: 115-125. doi:10.1016/j.ymeth.2023.11.003 .
doi: 10.1016/j.ymeth.2023.11.003
|
| [17] |
TAMOSIUNIENE R, MANOUVAKHOVA O, MESANGE P, et al. Dominant role for regulatory T cells in protecting females against pulmonary hypertension[J]. Circ Res, 2018, 122(12): 1689-1702. doi:10.1161/CIRCRESAHA.117.312058 .
doi: 10.1161/CIRCRESAHA.117.312058
|
| [18] |
SHU T, ZHANG J, ZHOU Y, et al. Eosinophils protect against pulmonary hypertension through 14-HDHA and 17-HDHA[J]. Eur Respir J, 2023, 61(3): 2200582. doi:10.1183/13993003.00582-2022 .
doi: 10.1183/13993003.00582-2022
|
| [19] |
陈睿迪, 王炜, 张若旸. 巨噬细胞在间质性肺疾病相关肺动脉高压中的作用[J]. 微生物学免疫学进展, 2025, 53(4): 87-93. doi:10.13309/j.cnki.pmi.2025.04.014 .
doi: 10.13309/j.cnki.pmi.2025.04.014
|
| [20] |
SHAPOURI-MOGHADDAM A, MOHAMMADIAN S, VAZINI H, et al. Macrophage plasticity, polarization, and function in health and disease[J]. J Cell Physiol, 2018, 233(9): 6425-6440. doi:10.1002/jcp.26429 .
doi: 10.1002/jcp.26429
|
| [21] |
ZHANG M Q, WANG C C, PANG X B, et al. Role of macrophages in pulmonary arterial hypertension[J]. Front Immunol, 2023, 14: 1152881. doi:10.3389/fimmu.2023.1152881 .
doi: 10.3389/fimmu.2023.1152881
|
| [22] |
FLORENTIN J, COPPIN E, VASAMSETTI S B, et al. Inflammatory macrophage expansion in pulmonary hypertension depends upon mobilization of blood-borne monocytes[J]. J Immunol, 2018, 200(10): 3612-3625. doi:10.4049/jimmunol.1701287 .
doi: 10.4049/jimmunol.1701287
|
| [23] |
AL-QAZAZI R, LIMA P D A, PRISCO S Z, et al. Macrophage-NLRP3 activation promotes right ventricle failure in pulmonary arterial hypertension[J]. Am J Respir Crit Care Med, 2022, 206(5): 608-624. doi:10.1164/rccm.202110-2274OC .
doi: 10.1164/rccm.202110-2274OC
|
| [24] |
DANG B, GAO Q, ZHANG L, et al. The glycolysis/HIF-1α axis defines the inflammatory role of IL-4-primed macrophages[J]. Cell Rep, 2023, 42(5): 112471. doi:10.1016/j.celrep.2023.112471 .
doi: 10.1016/j.celrep.2023.112471
|
| [25] |
NIE X, SHEN C, TAN J, et al. Periostin: A potential therapeutic target for pulmonary hypertension?[J]. Circ Res, 2020, 127(9): 1138-1152. doi:10.1161/CIRCRESAHA.120.316943 .
doi: 10.1161/CIRCRESAHA.120.316943
|